Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Arrhythmia is a common disease that may be caused by various cardiovascular diseases. According to statistics, 500,000 people die of severe arrhythmia every year in China, In the United States, approximately 540,000 patients die each year.This study will evaluate the effectiveness safety of sulcardine sulfate tablets in the patients with premature ventricular contractions (and non-sustained VT).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Arrhythmia is a common disease that may be caused by various cardiovascular diseases. The incident rate of various types of arrhythmias may be as high as 86-100% in patients who experience acute myocardial infarction within 10 days. Serious arrhythmias can endanger lives instantly. According to statistics, 500,000 people die of severe arrhythmia every year in China, which constitutes approximately 50% of the death rate for cardiovascular diseases. In the United States, among 1,500,000 myocardial infarction patients, approximately 540,000 patients die each year, which is mainly caused by ventricular fibrillation (VF) and sudden cardiac death (SCD).

Initially at least 24 subjects who meet the inclusion criteria and do not meet the exclusion criteria will be enrolled into either of two dose levels under a 3:1 randomization (active:placebo) take sulcardine sulfate tablets.Dose levels may be dropped, an intermediate dose level added as needed to deemed appropriate following review of safety and tolerability data at the prior dose level(200mg,400mg). A safety review committee will review data from all enrolled subjects at the simultaneous completion of Dosing Cohort 1 and 2 prior to advancement to the final dose level (800mg BID).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Ventricular Contraction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Premature ventricular contraction Frequent premature ventricular contraction, with or without a short array of non-sustained ventricular tachycardia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18-70 years old, body weight 45-80kg, and no sex preference.
2. Frequent premature ventricular contraction, the total number of premature ventricular beats indicated by Holter monitor greater than 3600 over 24 hours, with or without a short array of non-sustained ventricular tachycardia (more than 3, but fewer than 10 consecutive ventricular beats).
3. Negative pregnancy test result within 24 hours before the first dose for women of childbearing age. Females subjects of child bearing age must be on effective birth control (IUD or compliant use of oral contraceptive), have been surgically sterilized or abstain from sexual intercourse through the active dosing period and for the first 10 days after dosing.
4. Voluntary participation in the study and the ability to complete the screening and trial procedures, and to remain in the clinical study site throughout dosing period in accordance with the protocol.
5. Understand and voluntarily sign a written informed consent document.

Exclusion Criteria

1. History of Stage III-IV congestive heart failure.
2. Ejection fraction \<35% predicted
3. Polymorphic ventricular tachycardia, sustained ventricular tachycardia.
4. Congenital or acquired long QT syndrome, Torsade de Pointes, or an uncorrected QT-interval of \>480 ms; QRS\>120 ms.
5. Unstable angina, active myocarditis, rheumatic fever, or bacterial endocarditis, elevated Troponin T on work-up.
6. Sinus node dysfunction, atrioventricular block above first degree not controlled by pacemaker.
7. Complete left or right bundle branch block, or intraventricular block.
8. Hypotension, sitting resting blood pressure below 90/55mmHg.
9. Hypertension as defined by SBP\> 160mmHg and/or DBP \> 95mmHg
10. Sinus bradycardia (average heart rate lower than 50 beats/min).
11. Liver (liver function tests or bilirubin (direct or indirect) \>2XULN, history of cirrhosis or chronic active hepatitis.
12. Kidney dysfunction (plasma creatinine\>1.8 and creatinine clearance calculation \<30 as determined by Cockroft-Gault calculation) or electrolyte or acid-base balance disorders.
13. Taking digitalis, tricyclic antidepressants, β blockers, or calcium channel blockers within 5 half-lives for a given agent.
14. Thyroid dysfunction.
15. Serious respiratory diseases, Wolff-Parkinson-White syndrome; chronic obstructive pulmonary disease, asthma requiring medication
16. Cyanotic or other uncorrected significant congenital heart disease.
17. History of allergy to sulfonamides.
18. Taking other anti-arrhythmic drugs or medications that affect cardiac electrophysiology, or stop taking the above mentioned medications less than 5 half-life of the drug ago.
19. History of taking amiodarone within 1 years.
20. Severe neurosis, menopausal syndrome, chest pain caused by cervical spondylosis.
21. Diseases of the hematopoietic system, or mental illness.
22. Current evidence of alcohol abuse or history of illegal drug abuse.
23. Women of childbearing potential who are pregnant or nursing, or women of childbearing age who are not on effective birth control (IUD or compliant use of oral contraceptives and who have a positive urine pregnancy test prior to study.
24. Participation in a clinical trial of other drugs within 3 months.
25. Those considered not suitable to be selected by the investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jiangsu Furui Pharmaceuticals Co., Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing chao-yang hosipital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Peking university people's hosipital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gao M Ming, doctor

Role: primary

Liu J Mei, doctor

Role: backup

zhang Ping, doctor